News
- Author:
- Will Pass
Publish date: November 18, 2019
The pilot study used a sequential infusion of a third-generation chimeric antigen receptor T-cell “cocktail” targeting CD19 and CD22.
News
- Author:
- Will Pass
Publish date: November 16, 2019
The combination offers a viable alternative for a group of patients with historically “dismal” outcomes, investigators said.
News
- Author:
- Will Pass
Publish date: November 13, 2019
The registry is designed to give information back to patients, but physicians may be able to use the database to identify high-risk patients and gu...
News
- Author:
- Will Pass
Publish date: November 13, 2019
BOSTON – Bariatric surgery brought significant weight loss and resolution of multiple metabolic comorbidities.
News
- Author:
- Will Pass
Publish date: November 12, 2019
BOSTON – The nonsteroidal farnesoid X receptor agonist can reduce serum levels of liver biomarkers in patients with p...
News
- Author:
- Will Pass
Publish date: November 12, 2019
BOSTON – Kratom-associated liver damage involves a mixed pattern of hepatocellular and cholestatic injury.
News
- Author:
- Will Pass
Publish date: November 10, 2019
BOSTON – Lean patients with nonalcoholic fatty liver disease had almost twice the risk of advanced fibrosis as that of overweight and obese patient...
News
- Author:
- Will Pass
Publish date: November 8, 2019
BOSTON – Among 15 patients with severe alcoholic hepatitis, 87% responded to treatment (Lille score less than 0.45).
News
- Author:
- Will Pass
Publish date: November 8, 2019
BOSTON – In a phase 1b trial, treatment with tolerable doses of the bispecific antibody reduced hepatic fat fraction by a mean of 38%.
News
- Author:
- Will Pass
Publish date: November 8, 2019
BOSTON – Interim results of the open-label LIFT trial show positive results after 6 months of therapy.
News
- Author:
- Will Pass
Publish date: November 8, 2019
BOSTON – In a phase 1b trial, treatment with tolerable doses of the bispecific antibody reduced hepatic fat fraction by a mean of 38%.
News
- Author:
- Will Pass
Publish date: November 6, 2019
Experimental models have shown that ammonia exposure with astrocyte swelling and brain edema are potentiated by proinflammatory cytokines.
News
- Author:
- Will Pass
Publish date: October 23, 2019
After a median follow-up of 20.7 months, the addition of ramucirumab was associated with a significantly better median PFS, at 19.4 months, compare...
News
- Author:
- Will Pass
Publish date: October 23, 2019
The blood-based triage test, which relies upon four host proteins and one TB antigen, is another step closer toward standards proposed by the WHO.<...
News
- Author:
- Will Pass
Publish date: October 22, 2019
The benefit of trastuzumab was greater among patients with HR+ disease than those with HR– disease until the 5-year timepoint, after which HR statu...
